.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,791,097

« Back to Dashboard

Claims for Patent: 8,791,097

Title:Anti-tumor activity of CCI-779 in papillary renal cell cancer
Abstract: This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.
Inventor(s): Dukart; Gary (Ambler, PA), Gibbons, Jr.; James Joseph (Westwood, NJ), Berkenblit; Anna (Needham, MA), Feingold; Jay Marshall (Wynnewood, PA)
Assignee: Wyeth LLC (New York, NY)
Application Number:12/099,394
Patent Claims: 1. A method of treating papillary renal cell carcinoma in a mammal in need thereof, which comprises providing to said mammal an effective amount of CCI-779, wherein said papillary renal cell carcinoma is metastatic.

2. The method according to claim 1, wherein the papillary renal cell carcinoma is hereditary type I papillary renal cell carcinoma.

3. The method according to claim 1, wherein the papillary renal cell carcinoma is hereditary type II papillary renal cell carcinoma.

4. The method according to claim 1, wherein the papillary renal cell carcinoma is sporadic papillary renal cell carcinoma.

5. The method according to claim 1, wherein the papillary renal cell carcinoma is previously untreated papillary renal cell carcinoma.

6. The method according to claim 1, wherein the papillary renal cell carcinoma is advanced.

7. The method according to claim 1, wherein the CCI-779 is administered intravenously.

8. The method according to claim 1, wherein the CCI-779 is administered weekly for one to 24 months.

9. The method according to claim 1, wherein the CCI-779 is administered intravenously at a dose of 1 to 250 mg per week.

10. The method according to claim 9, wherein the CCI-779 is administered intravenously at a dose of 25 mg per week.

11. The method according to claim 1, wherein the CCI-779 is the sole anti-neoplastic agent in the regimen.

12. The method according to claim 1, wherein the CCI-779 is the sole active agent in the regimen.

13. The method according to claim 1, further comprising a further active agent, provided that the further active agent is not an interferon.

14. A method of treating papillary renal cell carcinoma in a mammal in need thereof, which comprises providing to said mammal an effective amount of CCI-779 in the absence of interferon alpha.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc